Physician profile
Vivek P Kushwaha
NPI 1982681730
$573,279.42
in general payments reported to CMS, 2019-2025
34 companies · $146K in 2025
The $146K reported for 2025 was more than what 95% of Orthopaedic Surgery of The Spine providers received nationally (typical 2025 total: $2,116).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109K · 2020: $5,270 · 2021: $24K · 2022: $69K · 2023: $102K · 2024: $117K · 2025: $146K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $343K · Travel and Lodging: $16K · Food and Beverage: $6,337.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $342,642.00 |
| Travel and Lodging | $16,007.30 |
| Food and Beverage | $6,336.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spineart Sa | $426,316.00 | 2021-2025 | Perla Tl - Degenerative Screw |
| Spinefrontier, INC. | $93,015.30 | 2019-2020 | |
| Spineart USA INC | $45,290.58 | 2019-2025 | Perla C, Perla Tl, Juliet Ll |
| Providence Medical Technology, INC. | $1,924.56 | 2020-2025 | |
| Spinal Elements, INC. | $1,137.17 | 2020-2022 | |
| Horizon Therapeutics Plc | $953.49 | 2019-2022 | |
| Medtronic, INC. | $777.70 | 2022-2024 | Mazor X System |
| Depuy Synthes Sales INC. | $378.57 | 2020-2023 | Expedium, Sentio, Viper |
| Abbott Laboratories | $373.70 | 2023-2024 | Proclaim, Eterna |
| Genesys Orthopedics Systems, L.L.C. | $369.05 | 2022 | |
| Alphatec Spine, INC | $268.86 | 2022 | |
| Stryker Corporation | $246.19 | 2020-2025 | Mako |
| Si-Bone, INC. | $202.91 | 2019-2024 | |
| Nevro Corp. | $199.74 | 2023 | Senza |
| Osseus Fusion Systems, LLC | $187.08 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carlsmed, INC. | $185.01 | 2022 | |
| Globus Medical, INC. | $174.15 | 2023 | Excelsiusgps Robotic Navigation System |
| Cerapedics INC. | $153.85 | 2022 | |
| Bioventus LLC | $148.89 | 2019-2023 | Bonescalpel |
| Next Science LLC | $145.57 | 2025 | Xperience, Blastx |
| Clariance, INC. | $141.85 | 2024 | Erisma-Lp |
| Heron Therapeutics, INC. | $141.52 | 2024 | Zynrelef |
| Nuvasive, INC. | $136.69 | 2019 | |
| Stability Biologics, LLC | $126.49 | 2022 | |
| Davol INC. | $117.81 | 2022 | |
| Intrinsic Therapeutics | $69.95 | 2025 | Barricaid Acd (Annular Closure Device) |
| Kowa Pharmaceuticals America, INC. | $23.32 | 2023 | Seglentis |
| Alafair Biosciences, INC. | $14.98 | 2025 | Versawrap |
| Pfizer INC. | $13.69 | 2019 | |
| Medtronic USA, INC. | $13.64 | 2020 | |
| Baudax Bio INC. | $12.96 | 2020 | |
| Radius Health, INC. | $12.96 | 2021 | |
| Electronic Waveform Lab, INC. | $5.19 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vivek Kushwaha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.